Intensification of Antiretroviral Therapy through Addition of Enfuvirtide in
C ombination antiretroviral therapy (cART) has substantially reduced mortality and morbidity in HIV-1-infected patients since its introduction in 1996 (1, 2). Even patients who initiate treatment relatively late in the course of the disease have been shown to benefit from cART (3, 4) . However, mortality and morbidity rates remain high in patients who enter HIV care with severe immunodeficiency (5) (6) (7) (8) , with most progressions to AIDS or death occurring in the first 6 months following the initiation of cART (2, 9) . Several studies have shown that the magnitude of the CD4 cell count response at 6 months is associated with a reduction in the rate of clinical progression (10) (11) (12) , including crude mortality (13) .
Current recommendations support initiating cART with two nucleoside reverse transcriptase inhibitors (NRTIs) plus efavirenz or a boosted protease inhibitor (PI). Optimization of ART in naive patients presenting with advanced HIV disease is needed to improve their immunological response and reduce the rate of clinical progression, especially in the first months following the initiation of treatment.
The aim of the randomized trial described here was to assess whether the addition of a fourth antiretroviral drug, namely, enfuvirtide, to a standard cART therapy would improve the increase in CD4 cell count in naive HIV-1-infected patients with advanced HIV disease.
MATERIALS AND METHODS
Study design. The ANRS 130 Apollo trial was an open-label, randomized, multicenter, nationwide, French clinical trial of three versus four antiretroviral drugs at the initial phase of antiretroviral treatment in severely immunosuppressed HIV-infected patients. Immunosuppression was defined as a CD4 cell count of Ͻ100/mm 3 if patients were asymptomatic or Ͻ200/mm 3 if patients were stage B or C, according to the 1993 Centers for Disease Control and Prevention classification. The trial statistician prepared the randomization list, and the codes were known only to him and the data services programmers and were unknown to the investigators and coordinators. Randomized treatment assignment was done using a central computer following the generated list, after eligibility criteria had been checked centrally at the clinical trials unit.
Patients from 38 HIV clinics in France were eligible if they met the following inclusion criteria: men or women aged Ն18 years old; HIV-1 infected, as assessed by a positive Western blot assay result; and naive for any ART with a CD4 cell count of Ͻ100/mm 3 if they were asymptomatic or Ͻ200/mm 3 if they had a past or present history of stage B or C disease, whatever the plasma HIV-1 RNA value. Patients were not eligible if they had HIV-2 infection or a cancer requiring radio-or chemotherapy, if they had received any immunomodulator therapy or HIV vaccine, or if they were pregnant, breast-feeding, or of childbearing age without effective contraception. Other exclusion criteria included creatinine clearance level of Ͻ60 ml/min, hemoglobin level of Ͻ8 g/dl, absolute neutrophil count of Ͻ750/mm 3 , platelet count of Ͻ50,000/mm 3 , and alkaline phosphatase or transaminases level Ն3 times the upper limit of the normal range (ULN). Patients with chronic hepatitis B or C were eligible if they did not have cirrhosis with a Child-Pugh score of B or C.
Written informed consent was obtained from all patients. The protocol was reviewed and approved by an ethics committee (Comité de Protection des Personnes) and competent health authority (Agence Française de Sécurité Sanitaire des Produits de Santé). The trial was conducted in accordance with the Declaration of Helsinki.
Study treatment regimens. All patients received a standard therapy of emtricitabine (FTC) coformulated with tenofovir disoproxil fumarate (Truvada; Gilead) combined with either lopinavir-ritonavir (400/100 mg; Kaletra; Abbott) twice daily or efavirenz (600 mg; Sustiva; Bristol-Myers Squibb) once daily, as per the choice of the local investigator. Standard therapy was defined before randomization.
Patients were centrally randomized (1:1) to receive either a standard therapy alone (control arm) or an intensified therapy through the addition of enfuvirtide (Fuzeon; Roche) at 90 mg subcutaneously twice daily to the standard therapy (enfuvirtide intensification arm). The duration of the enfuvirtide therapy in the intensification group was 24 weeks. All subjects were followed for 48 weeks. Randomization was stratified by clinical center, backbone therapy (efavirenz or boosted lopinavir), and clinical stage of HIV infection (stage C yes or no). If a patient had had a recent infection, no minimal delay between infection and initiation of ART was required.
Changes in the standard therapy were permitted throughout the duration of the study to control for the toxic effects of antiretroviral drugs, provided that patients continued to receive a combination of two nucleosides with either efavirenz or a boosted protease inhibitor. All patients received prophylaxis for Pneumocystis jirovecii pneumonia and toxoplasmosis until their CD4 cell count increased, per current guidelines (14) .
Outcome measures. The primary endpoint was the proportion of patients with a CD4 cell count of Ն200/mm 3 at week 24. We chose an immunological endpoint since the CD4 response is associated with a reduction in clinical progression, which was our main goal in this population of patients with advanced HIV disease. Secondary endpoints included the proportion of patients who reached plasma HIV-1 viral loads of Ͻ50 copies/ml at weeks 12, 24, and 48; the proportion of patients with a CD4 cell count of Ն200/mm 3 at week 48; the changes in CD4 cell count and plasma HIV-1 RNA levels between baseline and week 48; drug tolerability; the incidence of clinical HIV-and non-HIV-related events, death, and immune reconstitution and inflammatory syndrome (IRIS) reactions; and the proportion of patients who interrupted the therapeutic strategy allocated by randomization. Therapeutic strategy interruptions were defined as (i) interruption of enfuvirtide for more than 1 month in the intensification arm, (ii) addition of enfuvirtide in the control arm, or (iii) changes in the backbone therapy leading to administration of a combination other than two nucleosides and a boosted PI or two nucleosides and efavirenz.
Local laboratories assessed HIV-1 RNA levels and CD4 cell counts at screening, at enrollment, and at weeks 2, 4, 8, 12, 24, 36, and 48. An independent data and safety monitoring board regularly reviewed available safety and efficacy data. The severity of clinical and laboratory abnormalities was graded according to the ANRS scale for grading the severity of adverse events in adults. Investigators evaluated the association between the study regimen and each adverse event. Results of additional secondary endpoints (change in drug susceptibility and HIV-1 tropism) will be reported elsewhere.
IRIS case definition. IRIS was defined as evidence of symptoms temporally related to the initiation of cART with an increase in CD4 cell counts and/or a decrease in plasma HIV-1 RNA levels, consistent with an inflammatory condition, that could not be explained by a newly acquired infection, the failure of treatment of a previously diagnosed infection, or side effects of cART itself (15) . All cases of IRIS required review by an event review board.
Statistical analysis. We assumed that in the control arm, 30% of subjects would reach the primary efficacy endpoint. Thus, a sample size of 103 patients in each arm was necessary to provide at least 80% power, with an alpha risk of 5%, to detect a proportion of 50% of patients reaching the primary endpoint in the enfuvirtide arm. Primary efficacy analyses were conducted on an intent-to-treat basis. They included all enrolled patients, regardless of whether they received at least one dose of the study medication or whether they completed their allocated treatment. When CD4 cell count values were missing, they were considered treatment failures (i.e., CD4 count, Ͻ200/mm 3 ) in the primary efficacy analyses. Changes in CD4 cell count and HIV-1 RNA level were calculated on the basis of the available data. Differences were assessed using the chi-square test for comparing proportions and the Mann-Whitney/Wilcoxon test for comparing medians. In all analyses, the baseline was defined as the week 0 visit date. In the case of discontinuation of the trial, data were included up to the last visit date.
All statistical analyses were performed with SAS, version 9.1.3, service pack 2, software (SAS Institute).
RESULTS

Patient disposition and baseline characteristics. From March 2006 to December 2008
, 208 patients were screened and 195 patients were randomized. Among the 13 patients who were not randomized into the study, 5 had a CD4 cell count of Ͼ200 cells/ mm 3 at baseline. Other reasons are described in the trial profile (Fig. 1) . One hundred one patients were randomized in the enfuvirtide group and 94 were randomized in the control one.
One patient was not affiliated with the French social security system and had to be excluded from the analysis. One patient was lost to follow-up, eight patients (four in each arm) discontinued the study, including five who discontinued before week 0 (mostly because of patient demotivation) and did not receive study medication.
Patient baseline characteristics were well-balanced across the arms (Table 1) . Patients were primarily men (78%), and the mean age was 44 years. Most patients (82%) presented with a late HIV diagnosis (delay between diagnosis and study entry, less than 6 months). The baseline median CD4 cell count was 30/mm 3 ; 66% of the patients entered the study with a CD4 cell count of Ͻ50 cells/mm 3 . The baseline plasma HIV-1 RNA level was 5.4 log 10 copies/ml. Lopinavir-ritonavir was prescribed to 81% of patients, and efavirenz was prescribed to 19%. Most patients were stage C (73%), and 108 patients (56%) had an active AIDS event at baseline. Twenty-nine out of these 108 patients entered the study with multiple active AIDS events. The most common opportunistic infections were Pneumocystis jirovecii pneumonia (45 patients) and toxoplasmosis (16 patients).
Therapeutic strategy interruptions. Therapeutic strategy interruptions occurred in 20 patients, 16 in the intensification arm (15.8%) and 4 in the control arm (4.3%). In the intensification arm, 15 patients interrupted enfuvirtide (mostly definitely and due to poor convenience or local discomfort), and 1 patient switched from lopinavir to raltegravir because of diarrhea. In the control arm, one patient received enfuvirtide and raltegravir due to primary viral resistance at baseline, and three patients simulta- neously received a nonnucleoside reverse transcriptase inhibitor and a PI with an NRTI because of a poor virologic response; these were combined with raltegravir in one patient or with enfuvirtide in another patient. ) in the control arm (P ϭ 0.19). CD4 trends from week 0 to week 48 according to randomization are depicted in Fig. 2 . The lack of difference between the two arms persisted when considering different subgroups of patients according to their absolute CD4 cell count at baseline, i.e., Յ50, Ͼ50, and Յ100 or Ͼ100 cells/mm 3 . The proportion of patients with HIV-1 RNA loads of Ͻ50 copies/ml is depicted in Fig. 3 . At week 12, 45 patients (46%; 95% confidence interval [CI], 37 to 56%) in the enfuvirtide arm and 30 patients (33%; 95% CI, 24 to 43%) in the control arm had a plasma HIV-1 RNA load of Ͻ50 copies/ml (P ϭ 0.07). At week 24, 70 patients (74%; 95% CI, 65 to 83%) in the enfuvirtide arm and 51 patients (58%; 95% CI, 48 to 68%) in the control arm had a plasma HIV-1 RNA load of Ͻ50 copies/ml (P ϭ 0.02). Finally, similar proportions of patients in both arms reached HIV-1 RNA loads of Ͻ50 copies/ml at week 48 (79% [95% CI, 71 to 88%] in both arms). A lack of an early virological response, defined as a decrease in the HIV-1 RNA measure of less than 2 log 10 copies/ml at week 4, was reported in 12 patients (12%) and 16 patients (17%) in the enfuvirtide arm and in the control arm, respectively (P ϭ 0.31).
Clinical progression and adverse events. Clinical adverse events reported throughout the duration of the study are shown in Table 2 . There was no difference between arms in the percentage of patients reporting at least one clinical adverse event, a grade 3 or 4 clinical event, a serious event, or a study treatment-related event.
Enfuvirtide toxicity was limited to nodular or local inflammatory reactions, mostly grade 1 and 2, reported by 38 patients. Twenty patients (20%) and 12 patients (13%) in the enfuvirtide arm and in the control arm, respectively, experienced at least one AIDS event during follow-up (P ϭ 0.17). AIDS events are depicted in Table 3 . Of note, two-thirds of these events were new AIDS-defining diseases. Four deaths occurred, two in the intensification arm and two in the control arm. Three out of the four deaths were related to severe bacterial infections.
An IRIS event was reported in 15 patients (15%) and 20 patients (21%) in the enfuvirtide arm and in the control arm, respectively (P ϭ 0.26). The most frequent manifestations were mycobacterial infections (16 cases), folliculitis (9 cases), and nonrecurrent varicella-zoster (6 cases). The probability of devel- (2) 4 (2) oping an IRIS event was not different between the two arms (P ϭ 0.18). Grade 3 or 4 laboratory abnormalities were found in 21% of patients, with no difference between arms (P ϭ 0.45) ( Table 4) . Among 57 grade 3 or 4 laboratory abnormalities, only 7 were considered by the investigator to be related to study drugs (mostly hypophosphatemia, hypertriglyceridemia, or proteinuria related to emtricitabine-tenofovir) ( Table 5 ).
DISCUSSION
Even in Western countries, late diagnosis of HIV infection is frequent. In a British cohort of patients diagnosed with HIV-1 infection between 1996 and 2003, 15.3% had a CD4 cell count below 50 cells/mm 3 (8) . In a Spanish prospective cohort of antiretroviralnaive HIV-1-infected individuals, 18% had reached the AIDS stage and 32% had a CD4 cell count of Ͻ200 cells/mm 3 at enrollment (16) . Initial entry to medical care in the later stages of HIV disease is mainly due to late testing, particularly in populations with poor access to health care services, such as communities of color, young adults, immigrants, or poor city dwellers (17) (18) (19) . In a cross-sectional study conducted in North Carolina among patients who initiated HIV care for the first time, Dennis et al. reported that more than 40% of patients presented with a CD4 cell count of Ͻ200/mm 3 or an AIDS-defining event (18) . In a study at the Veterans Health Administration, more than half of the HIVinfected patients presented with AIDS (19) . In France, several studies have shown the same types of results. Among the 1,077 patients enrolled in the ANRS-EN12-VESPA survey, a representative sample of the French HIV-infected population, one-third of patients were classified as late testers, presenting with either clinical AIDS events or CD4 counts of Ͻ200/mm 3 at diagnosis (20) . The overall prevalence of delayed access to care (CD4 cell count of Ͻ200/mm 3 or an AIDS-defining event) was 35.7% in the French Hospital Database on HIV (ANRS CO4 FHDH) (21) .
Mortality and morbidity remain high in these late testers, despite cART. Indeed, in the FHDH, the mortality hazard ratio in patients with delayed access to care was 13.9 in the first 6 months and remained significantly higher than 1 during the subsequent 4 years, despite initiation of cART (21) . Thus, improving therapeutic efficacy is needed, and it is appropriate to evaluate combinations of more than three drugs to initiate treatment in this population of patients.
Few randomized studies have compared a four-antiretroviraldrug combination to standard cART. In three studies of PI-containing cART (22) (23) (24) , no beneficial effect was observed in the four-drug arm, but the PI regimen was probably not optimal (nelfinavir or unboosted indinavir). In the ACTG A5095 study, a combination of three NRTIs plus efavirenz was not more effective in reducing the plasma HIV load or increasing the CD4 cell count than two NRTIs plus efavirenz (25) . However, patients were not severely immunosuppressed in this trial, (i.e., baseline CD4 cell count, 240 cells/mm 3 ). In the present study, we chose enfuvirtide for several reasons. First, when the trial was designed, enfuvirtide was the only approved entry inhibitor and it seemed that it would be interesting to evaluate a combination including a drug interacting with targets other than reverse transcriptase or protease. Second, enfuvirtide appeared to be appropriate for patients with a poor clinical condition, considering its excellent systemic safety profile, the lack of drug interactions, and its parenteral administration, preventing a high pill burden in this context of four-drug therapy. The Apollo trial is the first randomized comparative clinical trial evaluating the effect of intensification of standard cART with enfuvirtide in naive HIV-1-infected patients with advanced disease. This strategy trial did not show a difference between the two arms in the proportion of patients with a CD4 cell count of Ն200/ mm 3 after 6 months of therapy. There was no trend of a better CD4 response in the intensified arm whatever the category of CD4 level at baseline (Յ50, 50 to 100, and Ͼ100/mm 3 ). Our results differ from those of the pilot study reported by Bonora et al. (26) , in which addition of enfuvirtide to cART at the initial phase of treatment resulted in an improved CD4 cell count. However, the latter study had two major limitations: the small sample size (11 patients per arm) and the observational nature of the comparison. In our study, although intensification of backbone cART did not result in immunological benefit, it induced a more rapid decline in plasma HIV-1 RNA levels, and the proportion of patients with HIV-1 loads below 50 copies/ml was significantly higher in the enfuvirtide arm. However, the more rapid decline of HIV-1 RNA at week 24 in the enfuvirtide arm did not translate into an improved CD4 cell count response or improved antiviral efficacy after week 48. The improved antiviral activity in the intensified arm suggests that the lack of an enhanced CD4 response did not result from impaired adherence to treatment. A virological substudy reporting resistance and viral tropism data did not show any difference in viral resistance at baseline. There was a trend for a more frequent switch from CCR5 to CXCR4 in the enfuvirtide arm; whether this could participate in the lack of an immunological benefit with enfuvirtide remains to be discussed (27) . There was no difference between arms in terms of new AIDS-defining events and/or death. The rate of clinical progression was similar to data from other studies performed in such a population (12, 28) , and our findings reflect the spectrum of opportunistic infections reported in resource-rich countries. As reported in the ACTG A5164 trial (12) , the most frequent opportunistic infections occurring as new AIDS-defining events under therapy were mycobacterial infections (nine events), esophageal candidiasis (five events), and cytomegalovirus infections (five events).
Interruption of the strategy occurred mainly in the intensification arm, with 15 patients stopping enfuvirtide mostly due to poor convenience or local discomfort. However, in spite of advanced HIV disease and constraints related to twice-daily subcutaneous administration, enfuvirtide appeared to be well accepted. As it could be anticipated by toxicity data available from previous studies, the incidence of grade 3 or 4 laboratory abnormalities was similar in both arms, confirming the biological safety of enfuvirtide.
The proportion of patients with IRIS was 18%. This is consistent with the incidence of IRIS in similar cohorts, in which 17 to 25% of patients initiating cART develop manifestations of the syndrome (29) (30) (31) . As reported in other studies, IRIS cases were most often dermatological or associated with mycobacterial infections. As expected, considering the CD4 cell count pattern over time, IRIS cases were not more frequent in the intensification arm, in spite of an improved early virological response.
The trial was powered to detect differences in an immunological surrogate marker of AIDS progression and survival, and our primary endpoint was based on the CD4 cell count response at 6 months. Several studies have shown that the impact of cART is primarily seen on morbidity and mortality events in the first 6 months of therapy (10) (11) (12) , suggesting that early improvement in immune responsiveness is critical to prevent clinical progression. In a retrospective analysis in urban Zambia, a CD4 cell count increase of less than 100/mm 3 at 6 months was associated with an increased risk of death after 6 months (13). Our primary endpoint was analyzed at the time point that, furthermore, matched with the end of enfuvirtide administration.
The backbone cART was a combination of tenofovir-emtricitabine with boosted lopinavir or efavirenz and was in agreement with the recommendations current at the time that the trial was conducted. In fact, boosted darunavir or atazanavir was not yet recommended as first-line therapy during this period. It has to be stressed that 80% of patients received boosted PI therapy; in this clinical setting, physicians tended to prefer the boosted PI-based antiretroviral regimen, probably because of its stronger genetic barrier, thus avoiding the selection of resistant viral strains that could affect potential choices for further lines of therapy (32) .
In conclusion, intensification of standard cART through the addition of enfuvirtide in naive HIV-1-infected patients with advanced disease did not improve the CD4 cell count response to treatment up to 48 weeks, although it induced a faster virological response. These results suggest that this therapeutic strategy would not decrease the risk of clinical progression following initiation of treatment in these subjects. However, intensification of cART merits further investigation with compounds from other classes, such as integrase inhibitors or CCR5 inhibitors.
